

UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK

In re: PURDUE PHARMA L.P., et al.,
Debtors


Case No.: 19-23649 (RDD)
Reporting Period October 1, 2019 to October 31, 2019
(including additional information for September 16, 2019 to September 30, 2019)

CORPORATE MONTHLY OPERATING REPORT

REQUIRED DOCUMENTS	Form No.	Document Attached	Explanation Attached
Schedule of Cash Receipts and Disbursements	MOR-1a	Yes	-
Bank Account Balances	MOR-1b	Yes	-
Consolidated Statement of Operations	MOR-2	Yes	-
Consolidated Balance Sheet	MOR-3	Yes	-
Schedule of Post-petition Taxes	MOR-4	-	Yes
Schedule of Payments to Insiders and Restructuring Professional Fees	MOR-5	Yes	-
Debtor Questionnaire	MOR-6	Yes	-

This Monthly Operating Report has been prepared solely for the purposes of complying with the monthly reporting requirements applicable in these chapter 11 cases and is in a format that the Debtors believe is acceptable to the United States Trustee. The financial information contained herein is limited in scope and covers a limited time period. Moreover, such information is preliminary and unaudited, and is not prepared in accordance with GAAP.

I declare under penalty of perjury that this report and the attached documents are true and correct to the best of my knowledge and belief.



Signature of Authorized Individual*

11/20/2019

Date

JON LOUG

Printed Name of Authorized Individual

11/20/2019

Date

*Authorized individual must be an officer, director or shareholder if debtor is a corporation.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period October 1, 2019 to October 31, 2019

SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS (\$)

Case No.	Debtor Entity Name:	Net Receipts ²	Net Disbursements ¹
19-23648	PURDUE PHARMA INC.	-	\$ 877,404
19-23649	PURDUE PHARMA L.P.	147,676,089.58	\$ 73,991,960
19-23650	PURDUE TRANSDERMAL TECHNOLOGIES, L.P.	-	\$ -
19-23651	PURDUE PHARMA MANUFACTURING L.P.	-	\$ 153,010
19-23652	PURDUE PHARMACEUTICALS L.P.	-	\$ 2,685,188
19-23653	IMBRIUM THERAPEUTICS L.P.	-	\$ 1,409,979
19-23654	ADLON THERAPEUTICS L.P.	-	\$ 2,315,694
19-23655	GREENFIELD BIO VENTURES L.P.	-	\$ 435,160
19-23656	SEVEN SEAS HILL CORP.	-	\$ -
19-23657	OPHIR GREEN CORP.	-	\$ -
19-23658	PURDUE PHARMA OF PUERTO RICO	-	\$ 4,583
19-23659	AVRIO HEALTH L.P.	-	\$ 4,128,546
19-23660	PURDUE PHARMACEUTICAL PRODUCTS L.P.	-	\$ -
19-23661	PURDUE NEUROSCIENCE COMPANY	-	\$ -
19-23662	NAYATT COVE LIFESCIENCE INC.	-	\$ 259,027
19-23663	BUTTON LAND L.P.	-	\$ -
19-23664	PAUL LAND INC.	-	\$ -
19-23665	QUIDNICK LAND L.P.	-	\$ -
19-23666	RHODES ASSOCIATES L.P.	-	\$ -
19-23667	RHODES PHARMACEUTICALS L.P.	18,831,206.63	\$ 11,553,095
19-23668	RHODES TECHNOLOGIES	82,406.54	\$ 4,429,653
19-23669	UDF LP	-	\$ -
19-23670	SVC PHARMA LP	-	\$ 132,992
19-23671	SVC PHARMA INC.	-	\$ -
Totals:		\$ 166,589,703	\$ 102,376,290

Footnotes

1) The Net Disbursements exclude intercompany transactions among Debtors

2) The Net Receipts exclude intercompany transactions among Debtors

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
October 31, 2019

BANK ACCOUNT BALANCES (\$)

Debtor	Bank	Account Number	Description	Balance as of Month End
Purdue Pharma L.P.	American Express National Bank (Restricted Cash)	xxxxxxx65041	CD	750,000
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx2400	Escrow	10,784,788
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx3900	Escrow	0
Purdue Pharma L.P.	East West Bank	xxxxxx9773	LOC/Collateral	10,002,910
Purdue Pharma L.P.	East West Bank	xxxxxx9808	LOC/Collateral	3,500,990
Purdue Pharma L.P.	East West Bank	xxxxxx9836	LOC/Collateral	1,660,470
Purdue Pharma L.P.	East West Bank	xxxxxx9136	Account	200,860,062
Purdue Pharma L.P.	Metropolitan Commercial Bank	xxxxxx4813	Account	100,251,606
Purdue Pharma L.P.	JPMorgan/Dreyfus Funds #761	xxxx7720	Money Market Fund	-
Purdue Pharma L.P.	Goldman Sachs #520	xxxx8266	Money Market Fund	299,077,061
Purdue Pharma L.P.	Goldman Sachs #506	xxxx0462	Money Market Fund	501,763,175
Purdue Pharma L.P.	JP Morgan Chase	xxxxx5837	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxx9129	Operating	22,198,930
Purdue Pharma L.P.	JP Morgan Chase	xxxxxxxxxx8509	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxx8921	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxx2890	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxx9388	ERISA	226,677
Purdue Pharma L.P.	East West Bank	xxxxxx9549	Operating	350,663
Purdue Pharma L.P.	East West Bank (Restricted Cash)	xxxxxx9304	Restricted Account	-
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx1100	Trust	10,194,773
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx6600	Trust	58,727,851
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxx6077	Trust	12,005,004
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxx4767	Trust	125,262,015
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx0300	Trust	10,314,809
Purdue Pharma L.P.	Bank of Oklahoma	xxxxx4018	Trust	27,005,493
Purdue Pharma Inc.	East West Bank	xxxxxx9213	Operating	1,305,455
Purdue Pharma Inc.	JP Morgan Chase	xxxxx2866	Operating	-
Purdue Pharmaceuticals L.P.	Wells Fargo (Restricted Cash)	xxxx5300	Trust	124,954
Imbrium Therapeutics L.P.	JP Morgan Chase	xxxxx1191	Operating	-
Imbrium Therapeutics L.P.	East West Bank	xxxxxx9241	Operating	-
Adlon Therapeutics L.P.	East West Bank	xxxxxx9248	Operating	-
Adlon Therapeutics L.P.	JP Morgan Chase	xxxxx5999	Operating	-
Greenfield BioVentures L.P.	JP Morgan Chase	xxxxx1118	Operating	-
Greenfield BioVentures L.P.	East West Bank	xxxxxx9234	Operating	-
Purdue Pharma of Puerto Rico	East West Bank	xxxxxx9185	Operating	-
Purdue Pharma of Puerto Rico	JP Morgan Chase	xxxxx5485	Operating	-
Avrio Health L.P.	East West Bank	xxxxxx9199	Operating	-
Avrio Health L.P.	JP Morgan Chase	xxxxx9278	Operating	-
Purdue Neuroscience Company	East West Bank	xxxxxx9227	Operating	-
Purdue Neuroscience Company	JP Morgan Chase	xxxxx6535	Operating	-
Nayatt Cove Lifescience Inc.	JP Morgan Chase	xxxxx8162	Operating	-
Nayatt Cove Lifescience Inc.	East West Bank	xxxxxx9220	Operating	-
Button Land L.P.	East West Bank	xxxxxx9297	Operating	-
Button Land L.P.	JP Morgan Chase	xxxxx1875	Operating	-
Paul Land Inc.	East West Bank	xxxxxx9290	Operating	-
Paul Land Inc.	JP Morgan Chase	xxxxx1859	Operating	-
Quidnick Land L.P.	JP Morgan Chase	xxxxx1891	Operating	-
Quidnick Land L.P.	East West Bank	xxxxxx9304	Operating	-
Rhodes Pharmaceuticals L.P.	JPMorgan/Dreyfus Funds #761	xxxx3154	Money Market Fund	-
Rhodes Pharmaceuticals L.P.	East West Bank	xxxxxx9269	Operating	-
Rhodes Pharmaceuticals L.P.	JP Morgan Chase	xxxxx6220	Operating	-
Rhodes Technologies	JPMorgan/Dreyfus Funds #761	xxxx3153	Money Market Fund	-
Rhodes Technologies	JP Morgan Chase	xxxxxxxxxx2509	Operating	-

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
October 31, 2019

BANK ACCOUNT BALANCES (\$)

Debtor	Bank	Account Number	Description	Balance as of Month End
Rhodes Technologies	JP Morgan Chase	xxxxxx6362	Operating	-
Rhodes Technologies	East West Bank	xxxxxx9262	Operating	-
SVC Pharma LP	JP Morgan Chase	xxxxxx9855	Operating	-
SVC Pharma LP	East West Bank	xxxxxx9276	Operating	-
SVC Pharma Inc.	JP Morgan Chase	xxxxxx9863	Operating	-
SVC Pharma Inc.	East West Bank	xxxxxx9283	Operating	-
Total				1,396,367,688

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period September 1, 2019 to September 30, 2019

CONSOLIDATED STATEMENT OF OPERATIONS (\$M) ^{1,2}
Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.

	Current Month	Cumulative Filing to Date ³
Net Sales	\$85	\$85
Cost of Goods Sold	(32)	(32)
Gross Profit	53	53
Sales and Promotion	(10)	(10)
Research and Development	(9)	(9)
General and Administrative	(9)	(9)
Legal Fees - Ordinary Course	1	1
Medical Affairs	(3)	(3)
Health Care Reform Fee	(3)	(3)
Other	1	1
Incentive Bonus	(5)	(5)
Total Operating Expenses	(37)	(37)
Operating Profit	16	16
Legal Fees - Non-Recurring	(28)	(28)
Other	7	7
Total Non-Operating Expenses	(21)	(21)
Loss	(\$5)	(\$5)

Footnotes

1) The numbers reflected in the Consolidated Statement of Operations are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period October 1, 2019 to October 31, 2019

CONSOLIDATED STATEMENT OF OPERATIONS (\$M) ^{1,2}
Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.

	Current Month	Cumulative Filing to Date ³
Net Sales	\$79	\$164
Cost of Goods Sold	(21)	(52)
Gross Profit	59	112
Sales and Promotion	(11)	(21)
Research and Development	(6)	(15)
General and Administrative	(6)	(15)
Legal Fees - Ordinary Course	(1)	-
Medical Affairs	(2)	(5)
Milestones & Alliances	(1)	(1)
Health Care Reform Fee	1	(2)
Other US	(2)	(1)
Incentive Bonus	(5)	(10)
Total Operating Expenses	(33)	(70)
Operating Profit	26	42
Legal Fees - Non-Recurring	(16)	(44)
Other	-	7
Total Non-Operating Expenses	(16)	(37)
Profit	\$10	\$5

Footnotes

1) The numbers reflected in the Consolidated Statement of Operations are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period September 1, 2019 to September 30, 2019

PURDUE PHARMA, INC. CONSOLIDATED STATEMENT OF OPERATIONS (\$000) ^{1,2}

	Current Month	Cumulative Filing to Date ³
Management Fee Income	\$25	\$25
General and Administrative Expenses	(2)	(2)
Operating Income	23	23
Income from Unconsolidated Associated Companies	11	11
Total Other Income	11	11
Pre-Tax Income	34	34
Income Tax Provision	(9)	(9)
Net Income	\$25	\$25

Footnotes

1) The numbers reflected in the Consolidated Statement of Operations are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period October 1, 2019 to October 31, 2019

PURDUE PHARMA, INC. CONSOLIDATED STATEMENT OF OPERATIONS (\$000) ^{1,2}

	Current Month	Cumulative Filing to Date ³
Management Fee Income	\$31	\$56
General and Administrative Expenses	(10)	(12)
Operating Income	21	44
Income from Unconsolidated Associated Companies	64	75
Total Other Income	64	75
Pre-Tax Income	85	119
Income Tax Provision	(23)	(32)
Net Income	\$62	\$87

Footnotes

1) The numbers reflected in the Consolidated Statement of Operations are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
September 30, 2019

CONSOLIDATED BALANCE SHEET (\$M) ^{1,2}	
Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.	
	Book Value
ASSETS	
CURRENT ASSETS	
Cash & Cash Equivalents	\$1,059
Accounts Receivable, Net	116
Due From Associated Companies	13
Other Receivables	2
Inventories, Net	99
Prepaid Expenses & Other Current Assets	87
Restricted Cash	13
TOTAL CURRENT ASSETS	1,389
Property and Equipment, net	144
Investments at Cost	26
Restricted Cash - Long-Term	259
Intangible Assets, Net	104
Other Assets	17
TOTAL ASSETS	\$1,939
LIABILITIES AND EQUITY	
CURRENT LIABILITIES	
Accounts Payable	\$39
Accrued Expenses	379
Due to Associated Companies	2
TOTAL CURRENT LIABILITIES	420
Other Liabilities	106
Liabilities Subject to Compromise	4
TOTAL LIABILITIES	530
EQUITY	
Retained Earnings & Partners' Capital	1,456
Accumulated Other Comprehensive Loss	(47)
TOTAL EQUITY	1,409
TOTAL LIABILITIES AND EQUITY	\$1,939

Footnotes

1) The numbers reflected in the Consolidated Balance Sheet are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
October 31, 2019

CONSOLIDATED BALANCE SHEET (\$M) ^{1,2}	
Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.	
	Book Value
ASSETS	
CURRENT ASSETS	
Cash & Cash Equivalents	\$1,145
Accounts Receivable, Net	85
Due From Associated Companies	12
Other Receivables	2
Inventories, Net	97
Prepaid Expenses & Other Current Assets	95
Restricted Cash	13
TOTAL CURRENT ASSETS	1,449
Property and Equipment, net	144
Investments at Cost	26
Restricted Cash - Long-Term	258
Intangible Assets, Net	103
Other Assets	17
TOTAL ASSETS	\$1,997
LIABILITIES AND EQUITY	
CURRENT LIABILITIES	
Accounts Payable	\$50
Accrued Expenses	412
TOTAL CURRENT LIABILITIES	462
Other Liabilities	103
Liabilities Subject to Compromise	13
TOTAL LIABILITIES	578
EQUITY	
Retained Earnings & Partners' Capital	1,466
Accumulated Other Comprehensive Loss	(47)
TOTAL EQUITY	1,419
TOTAL LIABILITIES AND EQUITY	\$1,997

Footnotes

1) The numbers reflected in the Consolidated Balance Sheet are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
September 30, 2019

PURDUE PHARMA, INC. CONSOLIDATED BALANCE SHEET (\$000) ^{1,2}

	Book Value
Assets	
Currents assets:	
Cash and cash equivalents	\$1,072
Prepaid expenses	213
Due from Associated Companies	2,110
Total current assets	3,395
Investments	10,222
Deferred income taxes	147
Total assets	\$13,764
Liabilities and equity	
Current liabilities:	
Accounts payable	\$2,861
Due to Associated Companies	233
Accrued Expenses	1
Total liabilities	3,095
Common stock	1
Additional paid-in capital	499
Retained earnings	10,234
Accumulated other comprehensive loss	(65)
Total equity	10,669
Total liabilities and equity	\$13,764

Footnotes

1) The numbers reflected in the Consolidated Balance Sheet are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
October 31, 2019

PURDUE PHARMA, INC. CONSOLIDATED BALANCE SHEET (\$000) ^{1,2}

	Book Value
Assets	
Currents assets:	
Cash and cash equivalents	\$1,303
Prepaid expenses	190
Due from Associated Companies	254
Total current assets	1,747
Investments	10,286
Deferred income taxes	147
Total assets	\$12,180
Liabilities and equity	
Current liabilities:	
Accounts payable	\$848
Due to Associated Companies	597
Accrued Expenses	4
Total liabilities	1,449
Common stock	1
Additional paid-in capital	499
Retained earnings	10,296
Accumulated other comprehensive loss	(65)
Total equity	10,731
Total liabilities and equity	\$12,180

Footnotes

1) The numbers reflected in the Consolidated Balance Sheet are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period October 1, 2019 to October 31, 2019


SCHEDULE OF POST PETITION TAXES

Office of the U. S. Trustee

Re: Monthly Operating Report Attestation Regarding Post Petition Taxes

The Debtor, PURDUE PHARMA L.P. and its affiliate Debtors hereby submit this attestation regarding post petition taxes.

All post petition taxes, which are not subject to dispute or reconciliation, are current. There are no material disputes or reconciliations.



Signature

11/20/2019

Jon Loung

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Period September 15, 2019 to September 30, 2019

SCHEDULE OF PAYMENTS TO INSIDERS (\$)

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE ¹
Compensation ²		
Chomiak, Caroline	12,772	12,772
Total Compensation	12,772	12,772
Director Fees		
Cola, Michael	175,000	175,000
Roncalli, Anthony	58,333	58,333
Total Director Fees	233,333	233,333
T&E Reimbursements		
Chomiak, Caroline	8,510	8,510
Kesselman, Marc L	5,222	5,222
Landau, Craig J	2,368	2,368
Lowne, Jonathan R	62	62
Lundie, David R	1,936	1,936
Mancinelli II, Vincent F	3,048	3,048
Medeiros, Paul	30	30
Shamblen, Randy	194	194
Strassburger, Philip C	1,702	1,702
Total T&E Reimbursements	23,072	23,072
Housing Payments		
Kesselman, Marc L	2,435	2,435
Total Housing Payments	2,435	2,435
Total Payments to Insiders	271,612	271,612

Footnotes

1) Represents payments made since the Commencement Date

2) Vehicles used by Craig J. Landau and Marc L. Kesselman are owned by Purdue Pharma L.P. Per-vehicle cost data is not recorded on a monthly basis.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period October 1, 2019 to October 31, 2019

SCHEDULE OF PAYMENTS TO INSIDERS (\$)

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE ¹
<i>Chomiak, Caroline</i>		
Chomiak, Caroline	26,324	39,096
Kesselman, Marc L ²	158,750	158,750
Landau, Craig J ²	216,418	216,418
Lowne, Jonathan R	81,374	81,374
Lundie, David R	64,920	64,920
Mancinelli II, Vincent F	39,874	39,874
Mazzi, Christian	56,701	56,701
Medeiros, Paul	49,646	49,646
Shamblen, Randy	39,028	39,028
Strassburger, Philip C	69,355	69,355
Total Compensation	802,388	815,160
<i>Director Fees</i>		
Boer, F Peter	175,000	175,000
Buckfire, Kenneth A	175,000	175,000
Cola, Michael	-	175,000
Dubel, John	175,000	175,000
Miller, Robert S	-	-
Pickett, Cecil	175,000	175,000
Roncalli, Anthony	58,333	116,667
Total Director Fees	758,333	991,667
<i>T&E Reimbursements</i>		
Boer, F Peter	2,125	2,125
Buckfire, Kenneth A	150	150
Chomiak, Caroline	5,925	14,435
Dubel, John	883	883
Kesselman, Marc L	7,760	12,982
Landau, Craig J	13,614	15,982
Lowne, Jonathan R	346	408
Lundie, David R	5,614	7,549
Mancinelli II, Vincent F	11,851	14,899
Mazzi, Christian	1,931	1,931
Medeiros, Paul	5,839	5,869
Miller, Robert S	1,349	1,349
Shamblen, Randy	2,450	2,645
Strassburger, Philip C	3,031	4,733
Total T&E Reimbursements	62,870	85,941
<i>Housing Payments</i>		
Kesselman, Marc L	2,435	4,870
Total Housing Payments	2,435	4,870
<i>Indemnification Payments</i>		
Butcher, James A	352	352

Total Indemnification Payments	352	352
<i>Payments to Independent Associated Companies</i>		
One Stamford Realty L.P.	752,590	752,590
Purdue Pharma Canada	266,320	266,320
TXP Services Inc.	106,406	106,406
Total Payments to Independent Associated Companies	1,125,317	1,125,317
Total Payments to Insiders	2,751,694	3,023,306

Footnotes

1) Represents payments made since the Commencement Date

2) Vehicles used by Craig J. Landau and Marc L. Kesselman are owned by Purdue Pharma L.P. Per-vehicle cost data is not recorded on a monthly basis.

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period September 15, 2019 to October 31, 2019

SCHEDULE OF RETAINED RESTRUCTURING PROFESSIONAL FEES (\$)

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE ¹
<i>Estate Professionals</i>		
Davis Polk & Wardwell LLP	-	-
AlixPartners, LLP	-	-
PJT Partners LP	-	-
Prime Clerk LLC	1,014,145	1,014,145
Total Estate Professionals	1,014,145	1,014,145
<i>Creditor Committee Professionals</i>		
Akin Gump Strauss Hauer & Feld LLP	-	-
Bayard, P.A.	-	-
Jefferies LLC	-	-
Province, Inc.	-	-
Total Creditor Committee Professionals	-	-
Total Retained Restructuring Professional Fees	1,014,145	1,014,145

Footnotes

1) Represents payments made since the Commencement Date

In re: PURDUE PHARMA L.P., et al.,
Debtors

Case No.: 19-23649 (RDD)
Reporting Period October 1, 2019 to October 31, 2019

DEBTOR QUESTIONNAIRE

Must be completed each month. If the answer to any of the questions is "Yes", provide a detailed explanation of each item. Attach additional sheets if necessary.	Yes	No	Comments
Have any assets been sold or transferred outside the normal course of business this reporting period?		X	
Have any funds been disbursed from any account other than a debtor in possession account this reporting period?		X	
Is the Debtor delinquent in the timely filing of any post-petition tax returns?		X	
Are workers compensation, general liability or other necessary insurance coverages expired or cancelled, or has the debtor received notice of expiration or cancellation of such policies?		X	
Is the Debtor delinquent in paying any insurance premium payment?		X	
Have any payments been made on pre-petition liabilities this reporting period?	X		Payments made pursuant to certain First Day Orders were made during the period.
Are any post petition receivables (accounts, notes or loans) due from related parties?		X	
Are any post petition payroll taxes past due?		X	
Are any post petition State or Federal income taxes past due?		X	
Are any post petition real estate taxes past due?		X	
Are any other post petition taxes past due?		X	
Have any pre-petition taxes been paid during this reporting period?	X		Payments have been made pursuant to the First Day Order authorizing the Debtors to pay certain prepetition taxes
Are any amounts owed to post petition creditors delinquent?		X	
Are any wage payments past due?		X	
Have any post petition loans been received by the Debtor from any party?		X	
Is the Debtor delinquent in paying any U.S. Trustee fees?		X	
Is the Debtor delinquent with any court ordered payments to attorneys or other professionals?		X	
Have the owners or shareholders received any compensation outside of the normal course of business?		X	